• 1.

    Colbert GB, et al. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol 2020; 13:563570. https://reference.medscape.com/medline/abstract/32511052

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Palmer BF, et al. Clinical management of hyperkalemia [published online November 4, 2020]. Mayo Clin Proc doi: 10.1016/j.mayocp.2020.06.014

  • 3.

    Palmer BF, Clegg DJ. Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity. Mayo Clin Proc 2016; 91:496508. doi: 10.1016/j.mayocp.2016.01.012

    • Crossref
    • Search Google Scholar
    • Export Citation

Novel Oral Potassium Binders

  • 1 Edgar V. Lerma, MD, FASN, is Clinical Professor of Medicine at the University of Illinois at Chicago.
Restricted access

Figure created using BioRender

Appropriate and timely management of hyperkalemia is an important component of a nephrology practice. Hyperkalemia can result from increased K+ intake in the diet, impaired distribution between intracellular and extracellular spaces, and decreased kidney excretion. Risk factors associated with the development of hyperkalemia include older age, male sex, diabetes, underlying kidney disease, as well as intake of certain medications that affect the renin angiotensin aldosterone system (RAAS).

Prior to the advent of sodium zirconium cyclosilicate (SZC) and patiromer, only sodium polystyrene sulfonate (SPS) was available as a potassium exchange resin (1). Approved by the

Save